Literature DB >> 18250415

Preassociation of IL-15 with IL-15R alpha-IgG1-Fc enhances its activity on proliferation of NK and CD8+/CD44high T cells and its antitumor action.

Sigrid Dubois1, Hiral J Patel, Meili Zhang, Thomas A Waldmann, Jürgen R Müller.   

Abstract

In the induction of an immune response, IL-15Ralpha on APCs transpresents IL-15 to NK and CD8(+)/CD44(high) T cells that express the IL-2/15Rbeta and gammac subunits only. In this study, we show data mimicking this transpresentation by using IL-15 preassociated with a chimeric protein that is comprised of the extracellular domain of murine IL-15Ralpha and the Fc portion of human IgG1. When tested in vitro, IL-15Ralpha-IgG1-Fc strongly increased the IL-15-mediated proliferation of murine NK and CD8(+)/CD44(high) T cells. The effect of IL-15Ralpha-IgG1-Fc was dependent on the presence of both IgG1-Fc and IL-15Ralpha. When injected into mice, IL-15Ralpha-IgG1-Fc enhanced the capacity of IL-15 to expand the number of NK and CD8(+)/CD44(high) T cells. The effect on cell numbers in vivo also depended on Fc receptor binding because reduced expansion was observed in FcRgamma(-/-) mice. NK cells cultured in IL-15/IL-15Ralpha-IgG1-Fc complex gained cytotoxic activity toward a number of NK-sensitive targets. When mice bearing the NK-sensitive syngeneic tumor B16 were treated, the presence of IL-15Ralpha-IgG1-Fc increased the antitumor activity of IL-15. Thus, a preassociation with IL-15Ralpha-IgG1-Fc enhances the activities of IL-15 in vivo and in vitro that may be useful in the treatment of tumors.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18250415     DOI: 10.4049/jimmunol.180.4.2099

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  109 in total

Review 1.  Multiple vaccinations: friend or foe.

Authors:  Sarah E Church; Shawn M Jensen; Christopher G Twitty; Keith Bahjat; Hong-Ming Hu; Walter J Urba; Bernard A Fox
Journal:  Cancer J       Date:  2011 Sep-Oct       Impact factor: 3.360

Review 2.  Cytokines that target immune killer cells against tumors.

Authors:  Jian Qiao; Yang-Xin Fu
Journal:  Cell Mol Immunol       Date:  2020-06-10       Impact factor: 11.530

3.  Augmented IL-15Rα expression by CD40 activation is critical in synergistic CD8 T cell-mediated antitumor activity of anti-CD40 antibody with IL-15 in TRAMP-C2 tumors in mice.

Authors:  Meili Zhang; Wei Ju; Zhengsheng Yao; Ping Yu; Bih-Rong Wei; R Mark Simpson; Rebecca Waitz; Marcella Fassò; James P Allison; Thomas A Waldmann
Journal:  J Immunol       Date:  2012-05-16       Impact factor: 5.422

4.  hIL-15-gene modified human natural killer cells (NKL-IL15) exhibit anti-human leukemia functions.

Authors:  Wen Jiang; Cai Zhang; Zhigang Tian; Jian Zhang
Journal:  J Cancer Res Clin Oncol       Date:  2018-05-08       Impact factor: 4.553

5.  Selective dependence of H2-M3-restricted CD8 responses on IL-15.

Authors:  Jürgen R Müller; Thomas A Waldmann; Sigrid Dubois
Journal:  J Immunol       Date:  2012-02-06       Impact factor: 5.422

6.  Mature natural killer cells with phenotypic and functional alterations accumulate upon sustained stimulation with IL-15/IL-15Ralpha complexes.

Authors:  Kutlu G Elpek; Mark P Rubinstein; Angelique Bellemare-Pelletier; Ananda W Goldrath; Shannon J Turley
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-22       Impact factor: 11.205

7.  ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial.

Authors:  John M Wrangle; Vamsidhar Velcheti; Manish R Patel; Elizabeth Garrett-Mayer; Elizabeth G Hill; James G Ravenel; Jeffrey S Miller; Mohammad Farhad; Kate Anderton; Kathryn Lindsey; Michele Taffaro-Neskey; Carol Sherman; Samantha Suriano; Marzena Swiderska-Syn; Amy Sion; Joni Harris; Andie R Edwards; Julie A Rytlewski; Catherine M Sanders; Erik C Yusko; Mark D Robinson; Carsten Krieg; William L Redmond; Jack O Egan; Peter R Rhode; Emily K Jeng; Amy D Rock; Hing C Wong; Mark P Rubinstein
Journal:  Lancet Oncol       Date:  2018-04-05       Impact factor: 41.316

8.  MHC class I and TCR avidity control the CD8 T cell response to IL-15/IL-15Rα complex.

Authors:  Thomas A Stoklasek; Sara L Colpitts; Henry M Smilowitz; Leo Lefrançois
Journal:  J Immunol       Date:  2010-11-01       Impact factor: 5.422

9.  IL-15 Agonists: The Cancer Cure Cytokine.

Authors:  Jennifer Wu
Journal:  J Mol Genet Med       Date:  2013-10-28

10.  Interleukin-15 and its receptor augment dendritic cell vaccination against the neu oncogene through the induction of antibodies partially independent of CD4 help.

Authors:  Jason C Steel; Charmaine A Ramlogan; Ping Yu; Yoshio Sakai; Guido Forni; Thomas A Waldmann; John C Morris
Journal:  Cancer Res       Date:  2010-01-19       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.